Kai Wucherpfennig
Has grant
Professor and Department Chair
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Recent Grants
Grant: Open
Strategy to Enhance Tumor Infiltration by Vaccine-induced T cells
Open Date: 2026-02-01
Close Date: 2028-01-31
Articles (17)
Supplementary Table S1: # Raw count of the genome-wide CRISPR screen for identifying T cell-mediated tumor killing in B2m-deficient cells. # MAGeCK results (Gene summary) for the genome-wide CRISPR screen from the B2m-deficient cells. # Gene log2FC in CRISPR screens from B2m-WT cells and B2m-KO cells. ## Common regulators of T cell mediated tumor killing in both B2m-WT and B2m-KO cells
Year:
2025
Supplementary Figure S3 Clinical courses of MRD+ cases and tumor expression profiles in MRD lesions. (A) The expression of potential therapeutic targets and genes of interest in the tumor region of sample 3A, the MRD sample from Pt-10. (B) The clinical course of the other three MRD+ cases, as represented by dynamic changes of serum CA-125 level, along with H&E staining, pathology annotations of tumor and non-tumor regions, as well as the expression of potential therapeutic targets and genes of interest in the MRD samples.
Year:
2025
Purpose: Minimal residual disease (MRD) after first-line treatment of advanced-stage ovarian cancer remains a long-standing barrier to cure. We investigated the prognostic and translational value of MRD detection by second-look laparoscopy (SLL) and ctDNA at the completion of first-line therapy. Experimental Design: Patients with high-grade epithelial ovarian cancer who had a complete clinical response to first-line therapy and underwent SLL and plasma collection for ctDNA were included. Progression-free survival (PFS) and overall survival (OS) were estimated based on MRD and clinicopathologic status. Spatial transcriptomics (GeoMx and Visium) and proteomics (CODEX) profiling were performed on serial samples from select patients. Results: Forty of 95 (42.1%) patients had surgically detected MRD, which was associated with worse PFS (median PFS 7.4 vs. 23.8 months; P P P = 0.013) in multivariable analysis. Among 44 patients who underwent SLL and had ctDNA testing, 34% (15/44) were ctDNA-positive, which was associated with worse PFS (6.4 vs. 28.1 months; P P = 0.008). We demonstrated the feasibility of spatial multiomics in studying MRD and their ability to provide hypothesis-generating observations, implicating the upregulation of the hypoxia signaling pathway, expression of multiple druggable targets ( CDK6 , GLS , MSLN , ERBB2 ), and immune exclusion in MRD lesions. Conclusions: Approximately half of patients in clinical remission after first-line therapy have assessable MRD, which can inform prognosis, therapeutic target discovery, and clinical trials.
Year:
2025
Supplementary Figure S4 Immune exclusion in the SLL sample 6B revealed by orthogonal spatial profiling. (A) CODEX profiling revealed two representative regions in the MRD sample (6B) of Pt-67. Region 1 located in the tumor margin where tumor cells interfaced with abundant CD8 T cells that demonstrated an exhausted state. This region was also enriched for interferon-stimulating signals. In contrast, region 2 represented tumor interior where very few CD8 T cells were observed. (B) Visium spatial profiling of the same sample as (A). CD8 T cell signals were detected in the tumor margin, which highly overlapped with the signals of immune checkpoint and interferon-stimulated genes.
Year:
2025
Supplementary Figure S2 Transcriptomic level comparisons of the tumor compartment between MRD and IDS samples using GeoMx data. (A) Volcano plot showing DEGs between the tumor compartment of MRD and IDS samples, with genes related to hypoxia signaling highlighted. (B) GSEA showing enriched pathways in the tumor compartment of MRD samples.
Year:
2025
Supplementary Figure S1 Clinical management of patients in the study cohort following SLL. *Many of these patients had the HRD assay performed retroactively on archival tissue and in this case, HRD status was not known in the upfront maintenance setting to guide therapy.
Year:
2025
Supplementary Figure 3. Digital quantification from immunohistochemistry. Digital quantification from immunohistochemistry for T cell subsets and marker analysis from paired tumor samples for five patients enrolled to cohort A.
Year:
2025
Supplementary Figure 1. CODEX panel and experimental procedure. CODEX panel used to identify tumor cell subpopulations, immune cell populations and key cellular markers. (B) Experimental workflow for 5 pre- and post-treatment FFPE samples. ROIs were selected for multiplexed imaging and downstream analysis. (C) U Map clusters show major cell populations. Immune populations showed similar clustering in pre- and post- treatment samples.
Year:
2025
Supplementary Figure 6. Cell-cell interaction analyses. Cell-cell interaction comparison in pre- and post-treatment tumor samples using CODEX for patient #5. (A) All significant interacting cell types shown in the entire analyzed tumor region as annotated. (B) Example images of cell – cell interactions showing interaction of CD163+ macrophages with GZMB+ CD8 T cells, CD163+ macrophages with GZMB+ CD4 T cells, CD68+ macrophages with GZMB+ CD8 T cells. The plus sign indicates interactions that were in close proximity at a one-cell distance (20 pixels).
Year:
2025
Purpose: Radiotherapy may enhance antitumor immune responses by several mechanisms, including induction of immunogenic cell death. We performed a phase 2 study of pembrolizumab with re-irradiation in patients with recurrent glioblastoma. Patients and Methods: Sixty patients with recurrent glioblastoma received pembrolizumab with re-irradiation alone (cohort A, bevacizumab-naïve; n = 30) or with bevacizumab continuation (cohort B, n = 30). Dual primary endpoints, including the overall response rate and overall survival (OS) at either 12 (OS-12; cohort A) or 6 months (OS-6; cohort B), were assessed per cohort relative to historic benchmarks. Paired paraffin-embedded formalin-fixed tumor samples were assessed for immunologic biomarkers by IHC using digital quantification and co-detection-by-indexing (CODEX). Results: Study therapy was well tolerated, with most toxicities being grade ≤3. For cohort B, the primary endpoint of OS-6 was achieved (57%); however, survival was not improved for cohort A patients. The overall response rate was 3.3% and 6.7% for cohorts A and B, respectively. CODEX analysis of paired tumor samples from five patients revealed an increase of activated T cells in the tumor microenvironment after study therapy. Conclusions: Compared with historic controls, re-irradiation plus pembrolizumab seemed to improve survival among bevacizumab-refractory patients but not among bevacizumab-naïve patients. CODEX revealed evidence of intratumoral infiltration of activated immune effector cells. A randomized, properly controlled trial of PD-1 blockade plus re-irradiation is warranted to further evaluate this regimen for bevacizumab-refractory patients, but alternative approaches are needed for bevacizumab-naïve patients.
Year:
2025
Year:
2025
Year:
2025
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Collaborators (26)
Daphne Haas-Kogan
Professor and Chair
Harvard University
Jianjun Gao
Assistant Professor
The University of Texas MD Anderson Cancer Center
Maxime Meylan
Dana-Farber Cancer Institute
Mario Suva
Professor
Harvard Medical School
Roni Wilke
The University of Texas MD Anderson Cancer Center
Anil Sood
Professor
The University of Texas MD Anderson Cancer Center
Sanghoon Lee
Associate Professor
The University of Texas MD Anderson Cancer Center
Amir Jazaeri
Professor
The University of Texas MD Anderson Cancer Center
Jeffrey How
Assistant Professor
The University of Texas MD Anderson Cancer Center
Tony J.C. Wang
Columbia University
Yibo Dai
The University of Texas MD Anderson Cancer Center
Shannon Westin
The University of Texas MD Anderson Cancer Center
Gwyn Richardson
Professor
The University of Texas MD Anderson Cancer Center
Jennifer A. Wargo
The University of Texas MD Anderson Cancer Center
Manoj Chelvanambi
The University of Texas MD Anderson Cancer Center
Pamela Soliman
Associate Professor
The University of Texas MD Anderson Cancer Center
Cara Haymaker
Associate Professor
The University of Texas MD Anderson Cancer Center
Keith Ligon
Chief of Neuropathology/Principal Investigator
Dana-Farber Cancer Institute
Shyam Tanguturi
Vice Chair, Network Strategy & Business Development
Dana-Farber Cancer Institute
Minetta Liu
Research Collaborator, Professor
Mayo Clinic
Ying Yuan
Professor
The University of Texas MD Anderson Cancer Center
Alexander Lazar
Professor
The University of Texas MD Anderson Cancer Center
Linghua Wang
Executive Director & Head
The University of Texas MD Anderson Cancer Center
David Boruta
Professor
The University of Texas MD Anderson Cancer Center
Yoshinaga Ito
Professor
Kyoto University
Stephen J Bagley
University of Pennsylvania
Make your next move.
Prepare your application
Review drafts before you send them.